VP4-2023: Sotorasib 960 mg versus 240 mg in pretreated KRAS G12C advanced NSCLC

被引：10

作者：

Hochmair, M. J. ^{[1
]}

Vermaelen, K. ^{[2
]}

Mountzios, G. ^{[3
,4
]}

Carcereny, E. ^{[5
]}

Dooms, C. ^{[6
]}

Lee, S. -h. ^{[7
]}

Morocz, E. M. ^{[8
]}

Kato, T. ^{[9
]}

Ciuleanu, T-e. ^{[10
]}

Dy, G. ^{[11
]}

Parente, M. B. M. C. S. ^{[12
]}

O'Byrne, K. J. ^{[13
]}

Chu, Q. s -c. ^{[14
]}

De Castro Jr, G. ^{[14
]}

Girard, N. ^{[15
]}

Snyder, W. ^{[16
]}

Tran, Q. ^{[16
]}

Kormany, W. ^{[16
]}

Houk, B. ^{[16
]}

Curioni-Fontecedro, A. ^{[17
]}

机构：

[1] Karl Landsteiner Inst Lung Res & Pulm Oncol, Dept Resp & Crit Care Med, Klin Florisdorf, Vienna, Austria

[2] UZ Gent Univ Ziekenhuis Gent, Dept Pulm Med, Ghent, Belgium

[3] Henry Dunant Hosp Ctr, Dept Med Oncol 4, Athens 11526, Greece

[4] Henry Dunant Hosp Ctr, Clin Trials Unit, Athens, Greece

[5] Catalan Inst Oncol Badalona, Badalona Appl Res Grp Oncol, Med Oncol, Badalona, Spain

[6] Univ Hosp KU Leuven, Dept Resp Dis, Leuven, Belgium

[7] Sungkyunkwan Univ, Samsung Med Ctr SMC, Dept Med, Div Hematol Oncol,Sch Med, Seoul, South Korea

[8] Pest Cty Hosp Pulmonol, Pulmonolgy, Torokbalint, Hungary

[9] Kanagawa Canc Ctr, Thorac Oncol Dept, Yokohama, Japan

[10] IOCN Oncol Inst Prof Dr Ion Chiricuta, Med Oncol Dept, Cluj Napoca, Romania

[11] Roswell Park Comprehens Canc Ctr, Med Dept, Buffalo, NY USA

[12] CHVNG E Ctr Hosp Vila Nova Gaia Espinho, Unidade 1, Pulmonol, EPE SNS, Porto, Portugal

[13] Princess Alexandra Hosp, Canc Serv, Metro South Hlth, Woolloongabba, Qld, Australia

[14] Univ Alberta, Cross Canc Inst, Med Oncol, Edmonton, AB, Canada

[15] Thorax Inst, Inst Curie, Paris, France

[16] Amgen Inc, Oncol, Thousand Oaks, CA USA

[17] Univ Hosp Zurich, Dept Med Oncol & Hematol, Zurich, Switzerland

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷 / 01期

关键词：

D O I：

10.1016/j.annonc.2023.10.790

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：142 / 144

页数：3

共 50 条

[31] Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study
Johnson, M. L.
de langen, A. J.
Waterhouse, D. M.
Mazieres, J.
Dingemans, A-M. C.
Mountzios, G.
Pless, M.
Wolf, J.
Schuler, M.
Lena, H.
Skoulidis, F.
Okamoto, I.
Kim, S-W.
Linardou, H.
Novello, S.
Chen, Y.
Solomon, B.
Obiozor, C.
Wang, Y.
Paz-Ares, L.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1417 - S1418
[32] Efficacy of Sotorasib Versus Standard Chemotherapy plus Immunotherapy in KRAS G12C Mutated Lung Cancer: A Comparative Study Modeling Real-World Data
Haddad, P.
Hammoud, D.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E28 - E28
[33] Trial in Progress: A Phase 1b Study of Sotorasib, a KRAS (G12C) Inhibitor, in Combination with other Anticancer Therapies in Patients with Advanced Solid Tumors Harboring KRAS p.G12C Mutation (CodeBreaK101)
Fakih, M.
Durm, G.
Govindan, R.
Falchook, G.
Soman, N.
Henary, H.
Hong, D. S.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S28 - S28
[34] Liquid biopsy to track KRAS G12C mutation at progressive disease in patients with advanced non-small cell lung cancer (NSCLC)
De Renzi, G.
Nicolazzo, C.
Pisegna, S.
Belardinilli, F.
Bottillo, I.
Grammatico, P.
Giannini, G.
Gelibter, A. J.
Gazzaniga, P.
ANNALS OF ONCOLOGY, 2021, 32 : S983 - S983
[35] Distant Metastasis Pattern and Baseline Clinicopathological Features from a Real-World KRAS G12C Mutant Cohort of Advanced NSCLC Patients
Mollica, L.
Intagliata, S.
Bonomi, L.
Ghilardi, L.
Morotti, D.
Ghirardi, G.
Antelmi, E.
Gianatti, A.
Carioli, G.
Muglia, R.
Marra, P.
Raimondi, F.
Ciaravino, G.
Di Marco, F.
Sironi, S.
Tondini, C. A.
Bettini, A. C.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S495 - S496
[36] A phase 1/2 study of VS-6766 in combination with sotorasib in patients with KRAS G12C mutant non-small cell lung cancer (NSCLC) (RAMP 203).
Govindan, Ramaswamy
Pachter, Jonathan A.
Koustenis, Andrew G.
Patrick, Gloria
Denis, Louis J.
CANCER RESEARCH, 2022, 82 (12)
[37] KRAS G12C mutated NSCLC and bladder cancer xenografts treated with sotorasib and adagrasib in combination with mTOR inhibitors show improved antitumor activity of nab-sirolimus vs everolimus
Hou, S.
Nieva, J.
Desai, N.
EUROPEAN JOURNAL OF CANCER, 2022, 174 : S58 - S59
[38] Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT)
Dingemans, Anne-Marie C.
Syrigos, Konstantinos
Livi, Lorenzo
Paulus, Astrid
Kim, Sang-We
Chen, Yuanbin
Felip, Enriqueta
Griesinger, Frank
Ohashi, Kadoaki
Zalcman, Gerard
Hughes, Brett Gordon Maxwell
Sorensen, Jens Benn
Blais, Normand
Ferreira, Carlos G. M.
Lindsay, Colin R.
Dziadziuszko, Rafal
Ward, Patrick J.
Obiozor, Cynthia Chinedu
Wang, Yang
Peters, Solange
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA9016 - LBA9016
[39] Efficacy and Safety of KRAS G12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study
Zhou, Qing
Meng, Xiangjiao
Sun, Longhua
Huang, Dingzhi
Yang, Nong
Yu, Yan
Zhao, Mingfang
Zhuang, Wu
Guo, Renhua
Hu, Yi
Pan, Yueyin
Shan, Jinlu
Sun, Meili
Yuan, Ying
Fan, Yun
Huang, Jianan
Liu, Lian
Chu, Qian
Wang, Xiuwen
Xu, Chongrui
Lin, Jiaxin
Huang, Jingjing
Huang, Mengna
Sun, Jiya
Zhang, Sujie
Zhou, Hui
Wu, Yi-Long
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (12) : 1630 - 1639
[40] Patient-reported outcomes from the CodeBreaK 200 phase III trial comparing sotorasib versus docetaxel in KRAS G12C-mutated NSCLC
Waterhouse, D. M.
Rothschild, S.
Dooms, C.
Mennecier, B.
Bozorgmehr, F.
Majem, M.
van den Heuvel, M.
Linardou, H.
Chul-Cho, B.
Roberts-Thomson, R.
Okamoto, I.
Blais, N.
Schvartsman, G.
Holmskov, K.
Chmielewska, I.
Forster, M.
Stollenwerk, B.
Obiozor, C. C.
Wang, Y.
Novello, S.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S37 - S38

← 1 2 3 4 5 →